PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annu...(Epoetin alfa in achieving transfus...),Health

alfa in achieving transfusion independence in transfusion-dependent MDS

patients.

-- Abstract: Drug Utilization and Cost Considerations of Erythropoiesis-

Stimulating Agents in Patients with Myelodysplastic Syndromes

Francois Laliberte, M.A., Groupe d'analyse, Ltee, Montreal, Quebec,

Canada

Publication Number 4611

A retrospective analysis of medical claims examined Epoetin alfa and

darbepoetin alfa dosing patterns, ESA treatment costs and red blood

cell transfusion use in order to characterize real-world utilization of

ESAs in adult patients with MDS.

-- Abstract: Assessment of Epoetin alfa in Patients with Myelodysplastic

Syndrome Utilizing an Electronic Medical Record Database

Bruce Feinberg, D.O., Georgia Cancer Center Oncology, Decatur, GA

Publication Number 5180

A retrospective, observational study, using electronic medical record

data from a large oncology/hematology practice in the southeastern

United States, was conducted to gain a better understanding of the

demographics, real-world treatment patterns and clinical outcomes for

patients with MDS receiving Epoetin alfa.

Data on PROCRIT and Real-World Practice Patterns

-- Poster: Erythropoiesis-Stimulating Agents for Chemotherapy Induced

Anemia: Analysis of an Electronic Medical Record Database within a

Large Oncology/Hematology Practice

Bruce Feinberg, D.O., Georgia Cancer Center Oncology, Decatur, GA

Presentation: Saturday, December 8, 2007; 5:30pm - 7:30pm, Hall B3 and

B4 in the Georgia World Congress Center (Poster Board Number 117,

Publication Number 963)

A retrospective, observational study using electronic medical record

data from a large oncology/hematology practice in the southeastern

United States was conducted to gain
'/>"/>